About
Peptide Conjugation Technology for Gene Delivery
Areas of Focus
Categories
Drug Delivery & FormulationBoston & New England
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
55
By Phase
PHASE2: 3PHASE1: 1
By Status
WITHDRAWN: 1RECRUITING: 1TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06833931Lead Sponsor
A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
PHASE2Withdrawn
Started: Dec 17, 2024 · Completed: May 28, 2025
NCT06667453Lead Sponsor
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
PHASE2Recruiting
24 participants
Started: Dec 10, 2024 · Completed: Aug 31, 2026
NCT06079736Lead Sponsor
A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment
PHASE2Terminated
7 participants
Started: Jan 8, 2024 · Completed: Aug 28, 2025
NCT06204809Lead Sponsor
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
PHASE1Active, not recruiting
24 participants
Started: Dec 12, 2023 · Completed: Oct 31, 2025
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...